Clinical observation of a patient with chronic COVID-19 and type 2 diabetes mellitus

This article describes the clinical observation of the patient who developed multiple new diseases after suffering a new coronavirus infection in 2020. Before COVID-19, she had only been diagnosed with hypertension. The patient experienced a severe case of COVID-19, developing pneumonia (CT2) in 2020 (at age 52), Four months later, diabetes mellitus was newly diagnosed, and three months later bronchial asthma and paroxysmal arrhythmias were diagnosed . Three years later, in 2024, the patient again experienced a new coronavirus infection, after which she noted a significant deterioration in cognitive function, hypertension control, and diabetes. Over the past year, progression of all microand macrovascular complications of diabetes mellitus has been noted – nephropathy (decrease in SCF from 55 to 21 ml per min), retinopathy (non-proliferative retinopathy), significant deterioration of polyneuropathy, progression of atherosclerosis, confirmed by instrumental methods (ultrasound Doppler imaging of the lower extremities, ultrasound Doppler imaging of the cerebral vessels). The data are consistent with severe post-COVID syndrome. The results are compared with global data. Risk factors for the development of post-COVID syndrome are identified. Associations of single-nucleotide polymorphisms of pleotropic genes with the development of severe post-COVID syndrome are found. Personalized therapy is identified.

1. Kim OT, Drapkina OM, Rodionova YuV. Russian-language publication activity of medical researchers in during the COVID-19 pandemic: “post-COVID-19 syndrome”. Cardiovascular Therapy and Prevention (Russian Federation). 2022;21(6):3299. (In Russ.) https://doi.org/10.15829/1728-8800-2022-3299.

2. Gorelov AV, Marzhokhova AR, Ploskirоva AA, Kharayeva ZF. Post-COVID syndrome, causes of development, risk factors, main pathogenetic mechanisms and manifestations (literature review). RMJ. 2025;(10):34‒40. (In Russ.) https://doi.org/10.32364/2225-2282-2025-10-5

3. Davis HE, Assaf GS, McCorkell L, Wei H, Low RJ, Re’em Y et al. Characterizing long COVID in an international cohort:7 months of symptoms and their impact. eClinicalMedicine. 2021;38:101019. https://doi.org/10.1016/j.eclinm.2021.101019.

4. Avdeev SN, Adasheva TV, Babak SL, Belyaeva IB, Bolieva LZ, Gubernatorova EE et al. Methodological recommendations «Features of Long-COVID infection clinical course. Therapeutic and rehabilitation measures». Therapy. 2022;1(Suppl):1–147. (In Russ.) https://doi.org/10.18565/therapy.2022.1suppl.1-147.

5. Valeeva FV, Khasanova KB, Valeeva EV, Kiseleva TA, Sozinova EA, Akhmetov II. Аssociation of rs1799883 polymorphism of the FABP2 gene with various carbohydrate metabolism disorders in residents of the Republic of Tatarstan. Medical Almanac. 2018;(6):116‒120. (In Russ.) Available at: https://www.elibrary.ru/smfryx.

6. Cao M, Zhang Y, Chen D, Zhong J, Zhang X, Yang L et al. Polymorphism in genes encoding two fatty acid binding proteins increases risk of ischemic stroke in a Chinese Han population. Front Genet. 2023;14:1056186. https://doi.org/10.3389/fgene.2023.1056186.

7. Zhang Z, Li H, Weng H, Zhou G, Chen H, Yang G et al. Genome-wide association analyses identified novel susceptibility loci for pulmonary embolism among Han Chinese population. BMC Med. 2023;21(1):153. https://doi.org/10.1186/s12916-023-02844-4.

8. Polat S, Şimşek ZÖ. Association between ACE (rs4343 and rs1799752), AGTR1 (rs5186), and PAI-1 (rs2227631) polymorphisms in the host and the severity of Covid-19 infection. Nucleosides Nucleotides Nucleic Acids. 2025;44(1):57‒78. https://doi.org/10.1080/15257770.2024.2387033.

9. Martínez-Nava Y, Ogaz-Escarpita MC, Reza-López SA, Leal-Berumen I. Diabetic kidney disease and polymorphisms of the ELMO1 and AGTR1 genes: Systematic review. Nefrologia. 2025;45(3):194‒213. https://doi.org/10.1016/j.nefroe.2025.02.005.

10. Ihsan M, Khan NU, Asim N, Ismail M, Almutairi MH, Ali I, Adams BD. Significant Association of Candidate Genes (AGTR1 and TGF-Β1) Polymorphism with Diabetic Nephropathy in Diabetes Mellitus Type 2 Patients. Cell Physiol Biochem. 2024;58(3):203‒211. https://doi.org/10.33594/000000702.

11. Bezmenova IN, Averyanova IV. 1166A>C polymorphism of the AGTR1 gene as a marker metabolic disorders in the North residents. Obesity and Metabolism. 2023;20(4):330‒337. (In Russ.) https://doi.org/10.14341/omet12986.

12. Li H, Louey JW, Choy KW, Liu DT, Chan WM, Chan YM et al. EDN1 Lys198Asn is associated with diabetic retinopathy in type 2 diabetes. Mol Vis. 2008;14:1698‒1704. Available at: https://pubmed.ncbi.nlm.nih.gov/18806884/.

13. Maslat AO, Al-Mahmood OM, Al Khawaja NM, Al-Shdefat R. Association of Genetic polymorphisms of EDN1 gene and Endothelin-1 level in patients with type 2 diabetes mellitus in the Jordanian population. Heliyon. 2023;10(1):e23676. https://doi.org/10.1016/j.heliyon.2023.e23676.

14. Ebrahimi N, Asadikaram G, Mohammadi A, Jahani Y, Moridi M, Masoumi M. The association of endothelin-1 gene polymorphism and its plasma levels with hypertension and coronary atherosclerosis. Arch Med Sci. 2019;17(3):613‒620. https://doi.org/10.5114/aoms.2019.86770.

15. Tu G, Fang Zh, Zhao Y, Wu Q. Association of +138I/D and Lys198Asn Polymorphisms in the Endothelin-1 Gene with Early Onset of Coronary Artery Disease among the Chinese Han Population. Med Sci Monit. 2020;26:e921542. https://doi.org/10.12659/MSM.921542.

16. Oleshko TB, Chaika IS, Oleshko TM, Harbuzova VY. Influence of LYS198ASN polymorphism of endothelin-1 gene on ischemic atherothrombotic stroke characteristics. Wiad Lek. 2020;73(4):657‒661. https://doi.org/10.36740/WLek202004106.

17. Fortis MF, Fraga LR, Boquett JA, Kowalski TW, Dutra CG, Gonçalves RO et al. Angiogenesis and oxidative stress-related gene variants in recurrent pregnancy loss. Reprod Fertil Dev. 2018;30(3):498–506. https://doi.org/10.1071/rd17117.

18. Sorokina Yu.A., Lovtsova L.V., Urakov A.L., Zanozina O.V. Genetic Polymorphism in Patients with Newly Diagnosed Type 2 Diabetes Mellitus. Sovremennye Tehnologii v Medicine. 2019;11(2):57–62. (In Russ.) https://doi.org/10.17691/stm2019.11.2.08.

19. Magamadov IS, Skorodumova EA, Kostenko VA, Pivovarova LP, Ariskina OB, Siverina AV, Skorodumova EG. Influence of endothelial nitric oxide syntase gene polymorphism on prognosis in patients after coronary bypass grafting. Translational Medicine. 2022;9(3):13‒23. (In Russ.) https://doi.org/10.18705/2311-4495-2022-9-3-13-23.

20. Fouda EAAM, Badr EA, Gawesh D, Mahmoud MA. The role of NOS3-rs1799983 and NOS3- rs2070744 SNP in occurrence of avascular necrosis as a post COVID-19 complication. BMC Med Genomics. 2024;17(1):217. https://doi.org/10.1186/s12920-024-01928-1.

21. Kohler HP, Grant PJ. Plasminogen-activator inhibitor type 1 and coronary artery disease. N Engl J Med. 2000;342(24):1792–1801. https://doi.org/10.1056/NEJM200006153422406.

22. Bayram B, Owen AR, Dudakovic A, Bettencourt JW, Limberg AK, Morrey ME et al. Elevated Expression of Plasminogen Activator Inhibitor (PAI-1/SERPINE1) is Independent from rs1799889 Genotypes in Arthrofibrosis. Meta Gene. 2021;28:100877. https://doi.org/10.1016/j.mgene.2021.100877.

23. Williams PT. Quantile-specific heritability of plasminogen activator inhibitor type-1 (PAI-1, aka SERPINE1) and other hemostatic factors. J Thromb Haemost. 2021;19(10):2559‒2571. https://doi.org/10.1111/jth.15468.

24. McCartney DL, Min JL, Richmond RC, Lu AT, Sobczyk MK, Davies G et al. Genome-wide association studies identify 137 genetic loci for DNA methylation biomarkers of aging. Genome Biol. 2021;22(1):194. https://doi.org/10.1186/s13059-021-02398-9.

25. Liu Y, Cheng J, Guo X, Mo J, Gao B, Zhou H, Wu Y, Li Z. The roles of PAI-1 gene polymorphisms in atherosclerotic diseases: A systematic review and meta-analysis involving 149,908 subjects. Gene. 2018;673:167‒173. https://doi.org/10.1016/j.gene.2018.06.040.

26. Chen J, Zhai C, Wang Z, Li R, Wu W, Hou K et al. The susceptibility of SERPINE1 rs1799889 SNP in diabetic vascular complications: a meta-analysis of fifty-one case-control studies. BMC Endocr Disord. 2021;21(1):195. https://doi.org/10.1186/s12902-021-00837-z.

27. Mariappan V, Adla D, Jangili S, Ranganadin P, Green SR, Mohammed S et al. Understanding COVID-19 outcome: Exploring the prognostic value of soluble biomarkers indicative of endothelial impairment. Cytokine. 2024;180:156673. https://doi.org/10.1016/j.cyto.2024.156673.

28. Nikolaeva LI, Stuchinskaya MD, Dedova AV, Shevchenko NG, Khlopova IN, Kruzhkova IS et al. Association of polymorphic variants of hemostatic system genes with the course of COVID-19. Voprosy Virusologii. 2023;68(5):445–453. (In Russ.) https://doi.org/10.36233/0507-4088-197

29. Maamar M, Artime A, Pariente E, Fierro P, Ruiz Y, Gutiérrez S et al. Post-COVID-19 syndrome, low-grade inflammation and inflammatory markers: a crosssectional study. Curr Med Res Opin. 2022;38(6):901‒909. https://doi.org/10.1080/03007995.2022.2042991.

30. Yong SJ. Long COVID or post-COVID-19 syndrome: putative pathophysiology, risk factors, and treatments. Infect Dis. 2021;53(10):737‒754. https://doi.org/10.1080/23744235.2021.1924397.

31. Szalai AJ, Wu J, Lange EM, McCrory MA, Langefeld CD, Williams A et al. Single-nucleotide polymorphisms in the C-reactive protein (CRP) gene promoter that affect transcription factor binding, alter transcriptional activity, and associate with differences in baseline serum CRP level. J Mol Med. 2005;83(6):440‒447. https://doi.org/10.1007/s00109-005-0658-0.

32. Gafarov VV, Gromova EA, Panov DO, Maksimov VN, Gagulin IV, Gafarova AV. Association of polymorphic marker Val158Met of COMT gene with depression in an open population 25–44 years old (WHO international program MONICA, epidemiological study). Neurology, Neuropsychiatry, Psychosomatics. 2021;13(2):19‒25. https://doi.org/10.14412/2074-2711-2021-2-19-25.

33. Rajkumar RP. Warriors, Worriers, and COVID-19: An Exploratory Study of the Catechol O-Methyltransferase Val158Met Polymorphism Across Populations. Cureus. 2020;12(8):e10103. https://doi.org/10.7759/cureus.10103.

34. Sudre CH, Murray B, Varsavsky T, Graham MS, Penfold RS, Bowyer RC et al. Attributes and predictors of long COVID. Nat Med. 2021;27(4):626‒631. https://doi.org/10.1038/s41591-021-01292-y.

35. Matviichuk A, Yerokhovych V, Zemskov S, Ilkiv Y, Gurianov V, Shaienko Z et al. Unveiling risk factors for post-COVID-19 syndrome development in people with type 2 diabetes. Front Endocrinol. 2024;15:1459171. https://doi.org/10.3389/fendo.2024.1459171.

36. Isaeva AV, Vetluzhskaya MV, Korobeynikova AN, Vlasova AV. Clinical phenotypes and features of the post-COVID syndrome course. Profilakticheskaya Meditsina. 2023;26(9):66–73. (In Russ.) https://doi.org/10.17116/profmed20232609166.

37. Zorina VV, Karaseva AA, Garbuzova EV, Afanasyeva AD, Duma SV, Sukhanov AV et al. Characteristics of The Neuropsychiatric Phenotype of Postcovid Syndrome. Russian Archive of Internal Medicine. 2025;15(5):346‒357. (In Russ.) https://doi.org/10.20514/2226-6704-2025-15-5-346-357.

38. Estiri H, Strasser ZH, Brat GA, Semenov YR. Evolving Phenotypes of nonhospitalized Patients that Indicate Long Covid. BMC Med. 2021;19(1):249. https://doi.org/10.1186/s12916-021-02115-0.

39. Gavkare AM, Nanaware N, Rayate AS, Mumbre S, Nagoba BS. COVID-19 associated diabetes mellitus: A review. World J Diabetes. 2022;13(9):729‒737. https://doi.org/10.4239/wjd.v13.i9.729.

40. Rizvi AA, Kathuria A, Al Mahmeed W, Al-Rasadi K, Al-Alawi K, Banach M et al. Post-COVID syndrome, inflammation, and diabetes. J Diabetes Complications. 2022;36(11):108336. https://doi.org/10.1016/j.jdiacomp.2022.108336.

41. Vasbinder A, Anderson E, Shadid H, Berlin H, Pan M, Azam TU et al. Inflammation, Hyperglycemia, and Adverse Outcomes in Individuals With Diabetes Mellitus Hospitalized for COVID-19. Diabetes Care. 2022;45(3):692–700. https://doi.org/10.2337/dc21-2102.

42. Scharf RE, Anaya J-M. Post-COVID Syndrome in Adults-An Overview. Viruses. 2023;15(3):675. https://doi.org/10.3390/v15030675.

43. Kim SH, Arora I, Hsia DS, Knowler WC, LeBlanc E, Mylonakis E et al. New-Onset Diabetes After COVID-19. J Clin Endocrinol Metab. 2023;108(11):e1164‒e1174. https://doi.org/10.1210/clinem/dgad284.

44. Karaseva AA, Khudiakova AD, Garbuzova EV, Ragino YuI, Logvinenko II. Severity of Postcovid Syndrome: A Systematic Review. Russian Archive of Internal Medicine. 2023;13(6):422-435. https://doi.org/10.20514/2226-6704-2023-13-6-422-435.

45. Ayoubkhani D, Khunti K, Nafilyan V, Maddox T, Humberstone B, Diamond I, Banerjee A. Post-covid syndrome in individuals admitted to hospital with covid-19: retrospective cohort study. BMJ. 2021;372:n693. https://doi.org/10.1136/bmj.n693.

46. Vikulova OК, Zheleznyakova AV, Serkov AA, Isakov MA, Vagapova GR, Valeeva FV et al. Multiplex analysis of post-Covid cardiorenal complications in patients with type 1 and type 2 diabetes mellitus according to the mobile diagnostic and treatment center (Diamobil). Problemy Endokrinologii. 2024;70(4):65‒74. (Russ.) https://doi.org/10.14341/probl13426.

47. Cuschieri S, Wilk P. Does Pre-existing Diabetes Correlate with Long COVID-19 in Europe? Evidence from the Analysis of the Survey of Health, Ageing and Retirement in Europe’s Corona Surveys. J Diabetes Res. 2024;2024:7459628. https://doi.org/10.1155/2024/7459628.

48. Tao Y, Zhao R, Han J, Li Y. Assessing the causal relationship between COVID-19 and post-COVID-19 syndrome: A Mendelian randomisation study. J Glob Health. 2023;13:06054. https://doi.org/10.7189/jogh.13.06054.

49. Udler MS. Type 2 Diabetes: Multiple Genes, Multiple Diseases. Curr Diab Rep. 2019;19(8):55. https://doi.org/10.1007/s11892-019-1169-7.

50. Belyakov NA, Trofimova TN, Rassokhin VV, Rybakova MG, Vasiliev BB. Postcovid syndrome ‒ polymorphism of disorders in a new coronavirus infection. HIV Infection and Immunosuppressive Disorders. 2021;13(4):7‒20. (In Russ.) https://doi.org/10.22328/2077-9828-2021-13-4-7-20.